Aurobindo Pharma’s subsidiary TheraNym has signed a grasp service settlement with pharma main Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) for contract manufacturing of biologicals.
TheraNym, which is able to manufacture the merchandise and provide to MSD, intends to invest about ₹1,000 crore for establishing a manufacturing facility with giant scale bioreactors for any mammalian cell tradition product and a vial filling isolator line for industrial drug product manufacturing upto 25-30 mn vials every year, Aurobindo mentioned in a submitting on Friday.
On the world of settlement, the drugmaker mentioned it’s for enlargement of the biologics manufacturing services of TheraNym in Medak district, close to right here, and to exploring the chances to enter into contract manufacturing operations for biologicals for each home and worldwide markets. Aurobindo Pharma shares closed 1.07% decrease at at ₹1,187 every on the BSE.
